SCHEMBL2198381

SCHEMBL2198381

Clc1ccc(CN(I)I)cc1.[Pt]=c1[nH]c(Cc2ccccc2)nn1Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NR1H2 P55055 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
STAT3 P40763 1/20 0.38
NR1H3 Q13133 1/20 0.38
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
GFER P55789 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
PRNP P04156 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194665 0.94 KDM4E (0.38) LMNASMN1; SMN2MEN1KMT2ANR1H3
SCHEMBL2195682 0.91 SMN1; SMN2 (0.39) LMNASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL2196435 0.90 MEN1 (0.39) LMNASMN1; SMN2NR1H2MAPTMEN1
SCHEMBL2197397 0.90 CACNA1G (0.38) SMN1; SMN2MAPTMEN1KMT2AGAA
SCHEMBL2195871 0.87 CXCR2 (0.37) SMN1; SMN2NR1H2NR1H3
SCHEMBL2196817 0.86 NR1H2 (0.36) SMN1; SMN2NR1H2MAPTNR1H3POLB
SCHEMBL2196581 0.79 HSD17B10 (0.36) LMNAMAPTMEN1KMT2ANR1H3
SCHEMBL2192152 0.78 HSD17B10 (0.38) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL2192353 0.77 ALDH1A1 (0.37) LMNASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL2199132 0.76 CYP2C19 (0.36) LMNASMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 LMNA 2301/4885SMN1; SMN2 4069/4885NR1H2 1458/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 LMNA 2301/4885SMN1; SMN2 4069/4885NR1H2 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.